Clinical Trials Logo

Attention Deficit-Hyperactivity clinical trials

View clinical trials related to Attention Deficit-Hyperactivity.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05077722 Completed - Clinical trials for Oppositional Defiant Disorder

Monitoring of Sleep and Behavior of Children 3-7 Years Old Receiving Parent-Child Interaction Therapy With the Help of Artificial Intelligence

PISTACHIo
Start date: March 24, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to develop an innovative wearable tracking protocol that will use Artificial Intelligence (AI) technology to monitor sleep and behavior of 3-7 year old children.

NCT ID: NCT03945175 Completed - Clinical trials for Attention Deficit-Hyperactivity

Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening

MYDAYIS
Start date: July 15, 2020
Phase: Phase 3
Study type: Interventional

Attention-deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder characterized by problems with sustaining attention, organization, planning, procrastination, daydreaming, restlessness, impulsivity and hyperactivity.This is an outpatient study for subjects between the ages of 18-60, who have an Attention deficit hyperactivity disorder (ADHD) diagnosis meeting all inclusion criteria and not meeting any of the exclusion criteria.

NCT ID: NCT00205699 Completed - Bipolar Disorder Clinical Trials

Metabolic Effects of Antipsychotics in Children

MEAC
Start date: April 2006
Phase: Phase 4
Study type: Interventional

The project aims to describe and compare the outcome of 12 weeks of prospective, randomized treatment with olanzapine, risperidone or aripiprazole on insulin action in skeletal muscle, liver and adipose tissue, abdominal fat mass, total body and fat-free mass, efficacy for symptoms of aggression and non-metabolic adverse events. Children aged 6-18 will be studied, exploring effects of stimulant therapy and age-related differences in vulnerability to treatment-induced adverse metabolic changes. Aims are addressed by measuring glucose and lipid kinetics with stable isotope tracers, body composition with dual energy x-ray absorptiometry and magnetic resonance imaging (MRI), and standardized assessments of efficacy and adverse events. Relevant data are critically needed to target clinical therapy and basic research, identify medical risks, and guide regulatory decisions in this vulnerable population.